| Symbol | GRI |
|---|---|
| Name | GRI BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 N 18TH STREET,TWO LOGAN SQUARE, SUITE 300,LA JOLLA, CA, PHILADELPHIA, Pennsylvania, 19103, United States |
| Telephone | +1 267 207-3606 |
| Fax | — |
| — | |
| Website | https://www.gribio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001824293 |
| Description | GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Companys lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Companys second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - GRI Bio, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001213900-26-055884 <b>Size:</b> 11 KB
Read moreGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Read moreGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Read moreGRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment
Read moreNew Form SCHEDULE 13G/A - GRI Bio, Inc. <b>Filed:</b> 2026-02-13 <b>AccNo:</b> 0001213900-26-016505 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - GRI Bio, Inc. <b>Filed:</b> 2026-02-10 <b>AccNo:</b> 0001493152-26-005944 <b>Size:</b> 6 KB
Read moreGRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Read moreGRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Read moreNew Form EFFECT - GRI Bio, Inc. <b>Filed:</b> 2026-01-30 <b>AccNo:</b> 9999999995-26-000436 <b>Size:</b> 1 KB
Read more